The link between abdominal obesity, metabolic syndrome and cardiovascular disease

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 4, 2007, Pages 319-326

  Ritchie, S A ^a   Connell, J M C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Abdominal obesity; Adipokines; Cardiometabolic risk; Cardiovascular disease; Insulin resistance; Metabolic syndrome; Visceral obesity

Indexed keywords

FATTY ACID; INTERLEUKIN 6; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA;

BLOOD; CARDIOVASCULAR DISEASE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; METABOLIC SYNDROME X; OBESITY; PHYSIOLOGY; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; FATTY ACIDS, NONESTERIFIED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; METABOLIC SYNDROME X; OBESITY; PIPERIDINES; PYRAZOLES; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34047266814     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2006.07.005     Document Type: Review

References (69)

1. WHO. WHO consultation, definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus - Geneva (1999), World Health Organisation
2. Balkau B., and Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16 5 (1999) 442-443
3. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 19 (2001) 2486-2497
4. Bloomgarden Z.T. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 26 3 (2003) 933-939
5. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 9491 (2005) 1059-1062
6. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 17 (2005) 2735-2752
7. Eckel R.H., Grundy S.M., and Zimmet P.Z. The Metabolic Syndrome. Lancet 365 9468 (2005) 1415-1428
8. Cameron A.J., Shaw J.E., and Zimmet P.Z. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 33 2 (2004) 351-375 [table of contents]
9. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28 11 (2005) 2745-2749
10. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 3 (2002) 356-359
11. Miccoli R., Bianchi C., Odoguardi L., Penno G., Caricato F., Giovannitti M.G., et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr Metab Cardiovasc Dis 15 (2005) 250-254
12. Bigaard J., Frederiksen K., Tjonneland A., Thomsen B.L., Overvad K., Heitmann B.L., et al. Waist circumference and body composition in relation to all-cause mortality in middle-aged men and women. Int J Obes (Lond) 29 7 (2005) 778-784
13. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., and Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med 164 10 (2004) 1066-1076
14. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 4 (2001) 683-689
15. McNeill A.M., Rosamond W.D., Girman C.J., Golden S.H., Schmidt M.I., East H.E., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28 2 (2005) 385-390
16. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 4 (2003) 414-419
17. Skilton MR, Moulin P, Serusclat A, Nony P, Bonnet F. A Comparison of the NCEP ATPIII, IDF and AHA/NHBLI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: Evidence for sex-specific differences. Atherosclerosis 2006 Apr 6 [Epub ahead of print].
18. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 10 4 (2003) S1-S10
19. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 2 (1999) 115-126
20. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 3 (2004) 813-823
21. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumour necrosis factor-alpha: direct role in obesity induced inflammation. Science 259 (1993) 87-91
22. Pasqui A.L., Pucetti L., Di Renzo M., Bruni F., Camarri A., Palazzuoli A., et al. Structural and functional abnormality of systemic microvessels in cardiac syndrome X. Nutr Metab Cardiovasc Dis 15 (2005) 56-64
23. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 16 (2005) 1685-1695
24. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 100 9 (1997) 2153-2157
25. Diamant M., Lamb H.J., van de Ree M.A., Endert E.L., Groeneveld Y., Bots M.L., et al. The association between abdominal visceral fat and carotid stiffness is mediated by circulating inflammatory markers in uncomplicated type 2 diabetes. J Clin Endocrinol Metab 90 3 (2005) 1495-1501
26. Xu H., Barnes G., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity related insulin resistance. J Clin Invest 112 (2003) 1821-1830
27. Mohanty P., Ghanim H., Hamouda W., Aljada A., Garg R., and Dandona P. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr 75 (2002) 722-767
28. Aljada A., Mohanty P., Ghanin H., Abdo T., Tripathy T., Chaudhuri A., et al. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for an inflammatory effect. Am J Clin Nutr 79 (2004) 682-690
29. Dandona P., Aljada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic Syndrome: A comprehensive perspective based on interaction between obesity, diabetes and inflammation. Circ 111 (2005) 1448-1454
30. Petrie J.R., Ueda S., Webb D.J., Elliott H.L., and Connell J.M. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 93 7 (1996) 1331-1333
31. Ritchie S.A., Ewart M.A., Perry C.G., Connell J.M., and Salt I.P. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond) 107 6 (2004) 519-532
32. Steinberg H.O., Chaker H., Leaming R., Johnson A., Brechtel G., and Baron A.D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97 11 (1996) 2601-2610
33. Cleland S.J., Petrie J.R., Small M., Elliott H.L., and Connell J.M. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 35 1 Pt 2 (2000) 507-511
34. Hutley L., and Prins J.B. Fat as an endocrine organ: Relationship to the Metabolic Syndrome. Am J Med Sci 330 6 (2005) 280-289
35. Pittas A.G., Joseph N.A., and Greenberg A.S. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 89 2 (2004) 447-452
36. Goldstein B.J., and Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 6 (2004) 2563-2568
37. Hotamisligil G.S. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 245 6 (1999) 621-625
38. Rask-Madsen C., Dominguez H., Ihlemann N., Hermann T., Kober L., and Torp-Pedersen C. Tumour necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108 15 (2003) 1815-1821
39. Hotamisligil G.S. Inflammatory pathways and insulin action. Int J Obesity 27 (2003) S53-S55
40. Bastard J.P., Maachi M., Van Nhieu J.T., Jardel C., Bruckert E., Grimaldi A., et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87 5 (2002) 2084-2089
41. Orshal J.M., and Khalil R.A. Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension 43 2 (2004) 434-444
42. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11 2 (2005) 183-190
43. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11 2 (2005) 191-198
44. Nakatani Y., Kaneto H., Kawamori D., Hatazaki M., Miyatsuka T., Matsuoka T.A., et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279 44 (2004) 45803-45809
45. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 1 (1999) 79-83
46. Shimabukuro M., Higa N., Asahi T., Oshiro Y., Takasu N., Tagawa T., et al. Hypoadiponectinaemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 88 7 (2003) 3236-3240
47. Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., et al. Adiponectin as a biomarker of the Metabolic syndrome. Circ J 68 (2004) 975-981
48. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F., and Rimm E. Plasma Adiponectin and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
49. Saha A.K., Avilucea P.R., Ye J.M., Assifi M.M., Kraegen E.W., and Ruderman N.B. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314 2 (2004) 580-585
50. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 8 (2001) 1167-1174
51. Kato H., Kashiwagi H., Shiraga M., Tadokoro S., Kamae T., Ujiie H., et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 26 1 (2006) 224-230
52. Lindsay R.S., Resnick H.E., Zhu J., Tun M.L., Howard B.V., Zhang Y., et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 25 3 (2005) e15-e16
53. Chen M.P., Tsai J.C., Chung F.M., Yang S.S., Hsing L.L., Shin S.J., et al. Hypoadiponectinaemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25 4 (2005) 821-826
54. Schulze M.B., Shai I., Rimm E.B., Li T., Rifai N., and Hu F.B. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54 2 (2005) 534-539
55. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signalling through a cAMP-dependent pathway. Circulation 102 11 (2000) 1296-1301
56. Wyne K.L. Free fatty acids and type 2 diabetes mellitus. Am J Med 115 Suppl. 8A (2003) 29S-36S
57. Laaksonen D.E., Lindstrom J., Lakka T.A., Eriksson J.G., Niskanen L., Wikstrom K., et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 54 1 (2005) 158-165
58. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 6 (2002) 393-403
59. Gill J.M.R., and Malkova D. Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity. Clinical Science 110 (2006) 409-425
60. Ziccardi P., Nappo F., Giugliano G., Esposito K., Marfella R., Cioffi M., et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105 7 (2002) 804-809
61. Brook R.D., Bard R.L., Glazewski L., Kehrer C., Bodary P.F., Eitzman D.L., et al. Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am J Cardiol 93 8 (2004) 1012-1016
62. Filippatos T.D., Kiortsis D.N., Liberopoulos E.N., Mikhailidis D.P., and Elisaf M.S. A review of the metabolic effects of sibutramine. Curr Med Res Opin 21 3 (2005) 457-468
63. Wadden T.A., Berkowitz R.I., Womble L.G., Sarwer D.B., Phelan S., Cato R.K., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353 20 (2005) 2111-2120
64. Hanusch-Enserer U., Cauza E., Spak M., Endler G., Dunky A., Tura A., et al. Improvement of insulin resistance and early atherosclerosis in patients after gastric banding. Obes Res 12 2 (2004) 284-291
65. Lichtman A.H., and Cravatt B.F. Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 115 5 (2005) 1130-1133
66. Van Gaal L.F., Rissanen A., Scheen A., Ziegler O., and Rossner S. Effect of rimonabant on weight reduction and cardiovascular risk. Lancet 366 9483 (2005) 369-370
67. Despres J.P., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 20 (2005) 2121-2134
68. Kaneto H., Nakatani Y., Miyatsuka T., Kawamori D., Matsuoka T.A., Matsuhisa M., et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 10 10 (2004) 1128-1132
69. Prattali R.R., Barreiro G.C., Caliseo C.T., Fugiwara F.Y., Ueno M., Prada P.O., et al. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in growth hormone treated animals. FEBS Lett 579 14 (2005) 3152-3158